IRB Company, Inc. (IRBCo), an independent review board that protects the rights and well-being of research volunteers participating in human research, announces its Full Accreditation status by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
Accreditation by AAHRPP offers assurances to research participants, researchers, sponsors, government regulators and the general public that IRBCo is focused on excellence in its human research protection programs.
"IRBCo has dedicated itself to remaining at the forefront of human research protections, and this voluntary process to earn accreditation required us to examine and review our operations and functions so that we remain a leading provider of central independent review board services," said Anil Sharma, MD, MBA, CIP, the Medical Director and Chief Executive Officer of IRBCo. "Accreditation validates our comprehensive program, which integrates ethical reviews, state-of-the-art technology and staff development."
As an independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven educational model to ensure that human research protection programs meet rigorous standards for quality and protection. To earn accreditation, organizations must provide evidence, through policies, procedures and practices, of their commitment to scientifically and ethically sound research and to continuous improvement.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ethical, Biosafety, and Scientific Review Considerations in Hematology and Oncology Clinical Trials
September 10th 2024The current oncology and hematology drug development pipeline features a wide array of large molecule therapeutics. As a result, clinical trial protocols have grown more complex, requiring sponsors, CROs, and research sites to tackle a variety of challenges that were less common with older, more traditional therapies.